Trial Profile
Efficacy of sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in the adults with immunocompromising conditions -A double blind randomized controlled trial-
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2020
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Acronyms CPI study
- 22 Dec 2016 New trial record